Tenon Medical, Inc. (TNON)
NASDAQ:TNON
Want to see TNON full AI Analyst Report?
TNON Stock Chart & Stats
$1.00
-$0.13(-5.94%)
At close: 4:00 PM EST
$1.00
-$0.13(-5.94%)
Day’s Range― - ―
52-Week Range$0.58 - $2.48
Previous CloseN/A
Volume74.29K
Average Volume (3M)70.32K
Market Cap
$7.24M
Enterprise Value$5.37M
Total Cash (Recent Filing)$4.61M
Total Debt (Recent Filing)$4.88M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding11,573,428
10 Day Avg. Volume65,213
30 Day Avg. Volume70,324
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.78
P/FCF Ratio-0.64
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit1.81
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$2.63Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Gross MarginsSustained top-line growth with a durable expansion in gross margin signals improving unit economics and better product mix. Higher gross margins (>60%) are structural for implantable device sales and, if revenue scales, provide a credible path to operating leverage and eventual profitability.
Expanding IP And Product PipelineA growing patent estate and staged product rollouts create sustainable differentiation in the SI joint market. IP protection reduces competitive erosion, supports premium pricing, and underpins multi-year commercialization and licensing opportunities as new Symmetry Plus enhancements and approaches come to market.
Commercial Execution And Surgeon TrainingInvestments in physician training and a staffed training center are structural drivers of adoption for surgical implants. Building a vetted user base increases procedure conversion rates and creates recurring implant demand, improving long-term market penetration and repeatable revenue streams.
Bears Say
Persistent Negative Operating Cash FlowLarge, ongoing cash burn undermines self-funding capacity and forces reliance on external capital. That structural deficit increases dilution risk, constrains reinvestment into sales and clinical studies, and could limit ability to sustain commercialization cadence absent material margin or revenue acceleration.
Elevated Leverage And Small Equity BaseA leveraged balance sheet with modest equity reduces financial flexibility and raises refinancing and covenant risk. Continued losses would pressure solvency metrics, likely forcing dilutive financings or higher-cost debt, impairing long-term capital structure stability and strategic optionality.
Nasdaq Listing Compliance RiskRegulatory listing risk is a structural overhang: potential delisting would harm liquidity, elevate capital costs, and could compel dilutive remedies (reverse split, financings). Management attention and resources may be diverted to compliance rather than commercialization until resolved.
Tenon Medical, Inc. News
TNON FAQ
What was Tenon Medical, Inc.’s price range in the past 12 months?
Tenon Medical, Inc. lowest stock price was $0.58 and its highest was $2.48 in the past 12 months.
What is Tenon Medical, Inc.’s market cap?
Tenon Medical, Inc.’s market cap is $7.24M.
When is Tenon Medical, Inc.’s upcoming earnings report date?
Tenon Medical, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Tenon Medical, Inc.’s earnings last quarter?
Tenon Medical, Inc. released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.305 by -$0.005.
Is Tenon Medical, Inc. overvalued?
According to Wall Street analysts Tenon Medical, Inc.’s price is currently Undervalued.
Does Tenon Medical, Inc. pay dividends?
Tenon Medical, Inc. does not currently pay dividends.
What is Tenon Medical, Inc.’s EPS estimate?
Tenon Medical, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Tenon Medical, Inc. have?
Tenon Medical, Inc. has 11,573,428 shares outstanding.
What happened to Tenon Medical, Inc.’s price movement after its last earnings report?
Tenon Medical, Inc. reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.305. Following the earnings report the stock price went down -11.548%.
Which hedge fund is a major shareholder of Tenon Medical, Inc.?
Currently, no hedge funds are holding shares in TNON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico. The company was founded in 2012 and is based in Los Gatos, California.
TNON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear progress: strong Q1 revenue (~+90% YoY), record gross profit and a large margin expansion (+24 percentage points), tangible commercial and IP investments, and added financing that extends runway. The company still operates at a net loss with OpEx elevated relative to a small revenue base and relies on successful commercial conversion and upcoming product launches to sustain momentum. Overall, the positives (sharp growth, margin gains, funding, IP and training investments) outweigh the risks, though meaningful execution is required to translate momentum into sustained profitability.View all TNON earnings summariesTNON Stock 12 Month Forecast
Average Price Target
$2.63
▲(162.50% Upside)
Technical Analysis
Strata Skin Sciences
―
Lifeward
―
enVVeno Medical
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Ownership Overview
13.19% Insiders
1.15% Mutual Funds
0.99% Other Institutional Investors
84.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---